Gemcitabine Clinical Trials
201 recruitingDrug
Phase 2124Phase 355Phase 150Not Applicable5Phase 41Early Phase 11
Showing 1–20 of 201 trials
Recruiting
Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,080 enrolled259 locationsNCT07213804
Recruiting
Phase 2
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Stage IV Nasopharyngeal Carcinoma AJCC v8Stage III Nasopharyngeal Carcinoma AJCC v8Stage II Nasopharyngeal Carcinoma AJCC v8
National Cancer Institute (NCI)50 enrolled85 locationsNCT06064097
Recruiting
Phase 3
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
National Cancer Institute (NCI)320 enrolled139 locationsNCT06524544
Recruiting
Phase 2
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
B-Cell Non-Hodgkins Lymphoma
Hoffmann-La Roche100 enrolled53 locationsNCT06806033
Recruiting
Phase 2
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Lung Neoplasm Malignant
Merck Sharp & Dohme LLC60 enrolled36 locationsNCT06788912
Recruiting
Phase 3
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.376 enrolled1 locationNCT07461454
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC780 enrolled264 locationsNCT06312137
Recruiting
Phase 1Phase 2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Ovarian Cancer Recurrent
Merck Sharp & Dohme LLC460 enrolled20 locationsNCT06843447
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled261 locationsNCT06841354
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled131 locationsNCT05139017
Recruiting
Phase 2
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting
Phase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled74 locationsNCT06545955
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled129 locationsNCT06770582
Recruiting
Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
BioNTech SE558 enrolled104 locationsNCT07173751
Recruiting
Phase 2
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Lung CancerNon-small Cell Lung CancerSmall Cell Lung Cancer
Fox Chase Cancer Center280 enrolled1 locationNCT05800587
Recruiting
Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cervical Cancer
Merck Sharp & Dohme LLC686 enrolled240 locationsNCT06459180
Recruiting
Phase 3
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma+2 more
SWOG Cancer Research Network94 enrolled274 locationsNCT06998940
Recruiting
Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Malignant Neoplasm of Bone and Articular CartilageMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple Sites+7 more
M.D. Anderson Cancer Center44 enrolled1 locationNCT03093909
Recruiting
Phase 3
Personalized Medicine for Advanced Biliary Cancer Patients
Biliary Tract Neoplasms
UNICANCER800 enrolled69 locationsNCT05615818
Recruiting
Phase 2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)156 enrolled79 locationsNCT06029270